Detail akcie Protagonist Therapc online

Business Summary: Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Protagonist Therapeutics Inc revenues decreased 85% to $38.6M. Net loss totaled $85.8M vs. income of $143.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Biopharmaceutical segment loss totaling $107.8M vs. income of $126.1M.